Journal of lung cancer最新文献

{"title":"From Lung Cancer Screening to Targeted Therapies: The Endless Race against Lung Cancer Morbidity and Mortality","authors":"A. Mathioudakis, G. Hardavella","doi":"10.4172/2576-1447.1000S1-E001","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-E001","url":null,"abstract":"Lung cancer represents an area of intensive research, owing to its prevalence and significant burden. More than one in five of all cancer deaths are attributed to lung cancer usually being unresectable at the time of diagnosis, lung cancer is associated with very poor outcomes therefore highlighting the importance of early diagnosis. Standard chemotherapy and conventional radiotherapy have limited effects on advanced stage disease therefore the need for novel, more effective therapeutic approaches has emerged Over the recent years, research has focused on two aspects: earlier diagnosis, to increase the proportion of patients with an operable disease on diagnosis, and targeted treatments, that are tailored to patients and are expected to further improve clinical outcomes. Early diagnosis is a rapidly evolving area, with several ongoing or completed trials assessing low-dose CT screening in high risk population for early detection of lung cancer. These include recently published early results from the UK Lung Cancer Screening Trial, a pilot randomized controlled trial that compared lung cancer screening versus usual care and recruited 4,055 individuals aged between 50-75 years, with a high risk of lung cancer, determined by factors such as smoking duration, occupational exposure to asbestos, family history or prior diagnosis of malignant tumour. This study concluded that lung cancer screening would be acceptable by individuals of screening age and would lead to a significant epidemiologic shift towards earlier diagnosis of lung cancer, with improved clinical outcomes [1]. Similarly, the Danish Lung Cancer Screening Trial which included 4,104 participants (aged between 50-70 years), supported the efficacy of low dose CT [2] in the early detection of lung cancer. Controversially, the DANTE Randomized Controlled Trial, with a study population of 2,450 participants, failed to prove the efficacy of low-dose CT screening, likely because of the limited statistical power of their sample [3]. Moreover, other studies commented on the physical and psychosocial burden associated with screening programs, false positive results and overdiagnosis and highlighted the need to take into account wellinformed patients’ values [4,5]. The NELSON Trial, an extensive ongoing randomised controlled trial with a study population of 15,822 high-risk patients is expected to shed more light. On the other side, targeted agents are also intensively studied as first or second line treatments and in particular new generations of TKIs (tyrosine kinase inhibitors) are trialled to overcome patterns of resistance.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasion of the Left Atrium by a Squamous Lung Cancer.","authors":"J. Macedo","doi":"10.4172/2576-1447.1000S1-014","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-014","url":null,"abstract":"Previously, he had no respiratory symptoms, until the day he came to the emergency room with sudden chest pain, with no irradiation and progressive intensity. A CT thoracic angiogram was performed and showed invasion of the left atrium (Figures 1-4). Bronchoscopy revealed in the right bronchi tree an exophytic mass with superficial vascularization and indirect signs of tumor. Biopsy confirmed a squamous lung cancer with moderate differentiation. Immunohistochemistry testing was performed and was positive for cytokeratin 5 and negative for cytokeratin 7, TTF1 and synaptophysin. This diagnosis wasn’t verified by immune staining for p63. The echocardiogram showed an enlarged left ventricle, diffuse hypo kinesia, left ventricle ejection fraction of 36%, dilatation of the left atrium (32 cm2) and right atrium (27 cm2); a hypo echoic mass was in contact with the left atrium, but without direct invasion.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dividing the Procedures into Lobectomy and Vertebrectomy for Large Lung Cancer Invading the Spine.","authors":"N. Motono, Aika Funasaki, Astushi Sekimura, K. Usuda, M. Kawaguchi, N. Kawahara, K. Usuda, H. Uramoto","doi":"10.4172/2576-1447.1000S1-018","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-018","url":null,"abstract":"Surgical treatment for lung cancer invading the spine remains challenging. Total vertebrectomy may be difficult by posterolateral thoracotomy alone, so a posterior midline incision may additionally be required. We performed by dividing the procedures into lobectomy and total vertebrectomy because en bloc resection was considered difficult due to the large volume of the lesions in the lung, chest wall, and vertebrae. Prior to the right upper lobectomy, we confirmed that the right upper lobe was interrupted temporarily and there was no congestion of residual lesion. The clamping technique is considered important in dividing the procedures into lobectomy and vertebrectomy.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"2 1","pages":"118-119"},"PeriodicalIF":0.0,"publicationDate":"2017-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44239563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Cases Lung Cancer Successfully Treated with 4-Hydroxybenzaldehyde afterSurgical Operations","authors":"K. Okazaki","doi":"10.4172/2576-1447.1000S1-017","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-017","url":null,"abstract":"In 1985, Kochi [1,2] reported a novel anti-tumor agent after acquiring a Japanese Patent in 1969. According to his patent, 4Hydroxybenzaldehyde is an anti-tumor agent without any side-effects. My impression is that this stuff is capable of preventing carcinogenesis when used quantitatively sufficiently. In order to treat developed cancers, you ought to start giving your cancer patient a small dose of the stuff because, otherwise, the patient may suffer from a serious hemorrhage of the tumor caused by excessive necroses. Therefore, lymphomas and leukemias can be treated more easily because these tumors have no blood vessels. Consequently, those who have these diseases can receive considerably large dose of the stuff.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2017-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43194661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ct DNA - What is itôs Advantage in Clinical Practice in Lung Cancer at thePresent Time","authors":"J. Macedo, M. Machado, Marta Diogo Pereira, J. Reis, F. Machado, M. Amaral, C. Moura, F. Carneiro, J. Maciel, P. Bastos, V. Hespanhol","doi":"10.4172/2576-1447.1000S1-016","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-016","url":null,"abstract":"","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2017-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43440257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Mutations and Humanized Monoclonal Antibody Treatment in Small-Cell Lung Cancer: A Review","authors":"de Moraes Junior Rm, Mota Gs, Carolino Mlo, Kerche-Silva Le","doi":"10.4172/2576-1447.1000S1-013","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-013","url":null,"abstract":"Small-cell lung cancer (SCLC) is one of the deadliest type of cancer with fast tumor growth and rapid metastatic dissemination. The most common genetic modifications associated with SCLC is connected to tumor suppressor and oncogenic genes, genes that control the cycle arrest of the cells. Standard treatment for SCLC is a combination of drugs such as cisplatin and etoposide and sometimes radiotherapy of the chest can be used. But these treatments have not been sufficient to decrease dead rate in SCLC patients and new drugs have been studied, specially humanized monoclonal antibodies (mAb). Therefore, the aim of this work is to review the main genetic alterations in SCLC and the mAb that has been tested to improve life expectancy in these patients.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"2 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46342880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Pulmonary Synovial Sarcoma: One Case Report.","authors":"Wang Li, C. Thakur, Sohanl . Gupta","doi":"10.4172/2576-1447.1000S1-015","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-015","url":null,"abstract":"Primary pulmonary synovial sarcoma (PPSS) is a rare disease. Diagnosis is made postoperatively following \u0000 resection of the tumor. We present an extremely rare case of PPSS in a 28-year-old, smoker-man whose chest imaging revealed a giant mass (5 × 6 × 7 cm), with dullness and decrease in breath sound in the left side of the \u0000 chest. A fiber optic bronchoscopy was performed and there was necrosis, hemorrhage, and left lower bronchial \u0000 obstruction. Subsequently diagnosis was confirmed by immunohistochemistry and the detection of a SYT-SSX \u0000 fusion gene. We believe that a diagnostic approach for lung sarcoma would provide helpful information to clinicians.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45234053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Circulatory Stiffening as a Complication of Stereotactic Ablative Body Radiotherapy Treatment to the Left Lung","authors":"Michael C Hartland, J. Fuller, L. Maloney, M. Dreosti, J. Buckley, G. Parfitt, K. Davison","doi":"10.4172/2576-1447.1000S1-012","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-012","url":null,"abstract":"","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44594729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Non-Small Cell Lung Cancer: Retrospective Study of PrognosticFactors","authors":"H. El-Hadaad, Y. Saleh, H. Wahba, M. A. Ahmad","doi":"10.4172/2576-1447.1000S1-011","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-011","url":null,"abstract":"Objective: The objective of the study is to investigate and improve our understanding of the impact of several potential prognostic factors on overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). \u0000Methods: Records of patients with advanced NSCLC (stage IIIB, IV) received first-line chemotherapy were reviewed. Age, gender, Eastern Cooperative Oncology Group performance status (ECOGPS), stage, histologic type, smoking status, leucocytic count, type of chemotherapy, albumin and hemoglobin level were evaluated for their prognostic significance in multivariate analysis. \u0000Results: A total of 140 patients with advanced NSCLC treated with first-line chemotherapy were identified. The median age was 54 (range from 35-83) years. The majority of patients were male (72%), had stage IIIB (67%) and were in PS 0or1 (75.7%). Forty-six percent had adenocarcinoma. Most patients were smokers (85%) and received platinum-based chemotherapy (78.6%).1-year OS was 39.3% with median survival time of 10 months (95% CI: 7.95-12).ECOGPS of 2(P=0.04), squamous histology (P=0.03), elevated leucocytic count (P=0.02),low hemoglobin level(P=0.02), smoking (P=0.03), low albumin level (P=0.05) and stage IV (P=0.01)were found to be independent prognostic factors for poor survival in multivariate analysis. While age (P=0.23), sex (P=1) and type of chemotherapy whether platinum-based or not (P=0.8) were insignificant factors for survival. \u0000Conclusion: From this study, we concluded that prognostic factors as smoking, ECOG PS of 2, squamous histology, stage IV, high leucocytic count, low hemoglobin level, low albumin level are found to have a significant impact on the survival while, gender, age, and type of chemotherapy are not. However, these results and additional information regarding prognostic factors in patients with advanced NSCLC in prospective studies should be validated.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"2 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44484132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solitary Non Small Cell Lung Cancer Metastasis to the Hypophysis: A CaseReport","authors":"M. Camandaroba","doi":"10.4172/2576-1447.1000S1-010","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-010","url":null,"abstract":"Introduction: There are few cases in the literature pituitary metastasis. In this situation, 20% of metastases are from lung cancers. In most cases are asymptomatic, being diagnosed by imaging tests, but poor patient prognosis. Case Presentation: A 65-years-old, Brazilian-Caucasian, male patient was admitted with clinical weight loss, fever and appetite loss. Imaging studies show lung mass and mass lesion and sellar and suprasellar. His blood hormone profile was compatiple with secondary pan-hypopituitarism due to destruction of hypophysis. A biopsy confirmed a metastatic lesion from lung adenocarcinoma to the pituitary. The patient was submitted to stereotatic radiotherapy and started chemotherapy with cisplatin 50 mg/m2 D1 and D8, and etoposide D1 to D5 each 28 days for two cycles concomitant to 3D-conformational irradiation of the lung nodule and mediastinal lymph nodes, followed by two additional cycles of cisplatin and etoposide as consolidation. Conclusion: The treatment decision when dealing with isolated non-small cell lung cancer metastasis to the hypophysis, always need a multidisciplinary discussion, since it can range from radiotherapy and chemotherapy to surgery, and its choice is based upon clinical presentation, prognosis and disease extension as well as patient preference, weighing risks and benefits of each available strategy.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}